An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)
AuthorsLe Pechoux, C.
AffiliationRadiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
MetadataShow full item record
AbstractBackground Primary analysis of Lung ART trial has shown (ESMO 2020) a non-statistically significant effect of PORT on disease-free survival (DFS) in N2 NSCLC patients (HR = 0�86 (95% CI 0�68-1�08]; p=0�18). However PORT was associated with a reduction of 51% in the risk of mediastinal relapse (MR). Patterns of relapse as well as prognostic factors of PORT efficacy warranted further investigations to determine which patients could benefit more from PORT. Methods Patients were eligible in Lung ART if they had a WHO performance status ?2, considered to have undergone complete resection with lymph node exploration, proven N2 disease +/- prior neo-adjuvant or adjuvant CT. DFS components (metastatic, mediastinal relapses and deaths) were analysed using competing risks approaches. Prognosis factors for DFS and OS were explored based on prespecified analyses coupled with an exploratory approach. Results 501 patients were randomised. Among DFS events, there are 161 (54%) metastatic relapses (including 61 (21%) brain metastases), 106 (36%) MR, and 29 (10%) deaths. Three-year metastatic relapse-free survival is 72.31% [66.5;77.1] and 68.47% [61.7;74] in the control and PORT arms, respectively; 3-year MR-free survival is 72.26% [65.9;77.4] and 86.06% [81.2;89.7], respectively. MR occurs mainly within initially involved nodes (66% in control arm, 47% in PORT arm) and significantly less in PORT arm (unadjusted sub-distribution HR= 0.46 (95% CI [0.3;0.7]). The 3 most frequent sites of MR are stations 7 (47%), 4L (42%), 4R (37%) for left-sided tumours; stations 4R (48%), 2R (44%) and 7 (41%) for right-sided tumours. Prognostic factors for DFS include quality of resection, extent of mediastinal involvement and lymph node ratio (involved / explored), with differential effects according to DFS components. With regards to overall survival, extent of nodal involvement is a significant prognostic factor whereas PORT (HR = 0.98 [0.7;1.4]) is not. Conclusions Use of PORT in N2 NSCLC patients reduces the risk of MR, but has no significant impact on DFS. Prognostic factors associated with different DFS components were identified which may allow a personalized prescription of PORT.
CitationLe Pechoux C, Barlesi F, Pourel N, Faivre-Finn C, Lerouge D, Zalcman G, et al. 1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK). Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S939.
JournalAnnals of Oncology